Australia's CSL falls on Jefferies downgrade to "hold"
BUZZ-Australia's CSL falls on Jefferies downgrade to "hold" ** Shares of biotechnology major CSL Ltd CSL.AX fall as much as 2.5% to A$95.16, their lowest level since May 12
** Jefferies downgrades CSL to "hold" from "buy", citing limited near-term growth in its Vifor division amid rising competitive pressures
** Cuts price target to A$108 from A$195 after shifting to peer‑based valuation and lowering earnings forecasts
** Says CSL Vifor faces pricing pressure from generic iron products and insurer step-edits favouring lower-cost treatments
** Adds lower-than-expected CHF/USD forex forecast to impact Vifor revenue and profit
** Stock down 43.7% YTD, including the day's moves
(Reporting by Roushni Nair in Bengaluru)
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX